Xavier Gitton

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

Helen J. Lachmann, Isabelle Koné‐Paut, Jasmin Kuemmerle‐Deschner et al. · New England Journal of Medicine · 2009 · 842 citations · Full text

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

Thomas J. Schnitzer, Gerd R Burmester, Eduardo Mysler et al. · The Lancet · 2004 · 700 citations

Rheumatology, Anti-inflammatory, Anti-inflammatory Agents +9

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

Michael E. Farkouh, Howard S. Kirshner, Robert A. Harrington et al. · The Lancet · 2004 · 490 citations

Rheumatoid Disorder, Rheumatology, Anti-inflammatory +10

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

Rieke Alten, Juan J. Gómez‐Reino, Patrick Durez et al. · BMC Musculoskeletal Disorders · 2011 · 149 citations · Full text

Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four‐week, multicenter, randomized, double‐blind, placebo‐controlled trial

Thomas J. Schnitzer, Jannie Beier, Piet Geusens et al. · Arthritis Care & Research · 2004 · 55 citations